Project Details
Description
PROJECT SUMMARY
Tuberculosis (TB) is among the leading causes of mortality worldwide with an estimated 2 billion individuals
currently infected. Latent tuberculosis infection (LTBI) is the most common form of TB infection affecting 13
million Americans. While many with LTBI remain asymptomatic, an estimated 10% of immunocompetent patients
with LTBI will reactivate to active TB, and will become infectious. LTBI is treatable with a prolonged antibiotic
treatment; however, potential side effects motivate the development of new diagnostic approaches that can
identify with high specificity patients at the highest risk of reactivation, for who therapy would be most beneficial.
The tuberculin skin test (TST) and interferon-γ release assays (IGRAs) are commonly used for TB and LTBI
screening. Both tests provide good measures of TB exposure; however, neither is effective at diagnosing LTBI
(positive predictive values
Status | Finished |
---|---|
Effective start/end date | 9/5/19 → 8/31/23 |
Funding
- National Institute of Allergy and Infectious Diseases: $719,615.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.